Seeking Alpha
 

Neptune Technologies & Bioresources Inc (NEPT)

- NASDAQ
  • Tue, Jul. 14, 7:27 AM
    • Neptune Technologies (NEPT +8.3%) FQ1 results: Revenues: $2.7M (-27.0%); COGS: $3.5M (+9.4%); R&D Expense: $1.8M (-14.3%); SG&A: $3.5M (-56.8%); Operating Loss: ($6.2M) (+22.5%); Net Loss: ($5M) (-13.6%); Loss Per Share: ($0.06) (unch); Quick Assets: $23.7M (-14.1%).
    • No guidance given.
    | Comment!
  • Mon, Jul. 13, 5:13 PM
    • Neptune Technologies (NASDAQ:NEPT): FQ1 Net loss of $4.96M
    • Revenue of $2.7M (-26.8% Y/Y)
    • Press Release
    | 2 Comments
  • Sun, Jul. 12, 5:35 PM
  • Thu, May 28, 12:47 PM
    | 2 Comments
  • Thu, May 28, 6:47 AM
    • Neptune Technologies (NEPT +2.9%) FQ4 results: Revenues: $4M (+8.1%); Adjusted EBITDA Loss: ($10M) (-270.4%); Net Loss: ($10.7M) (-723.1%).
    • FY2015 results: Revenues: $15.1M (-22.6%); Adjusted EBITDA Loss: ($32.9M) (-72.3%); Net Loss: ($29.8M) (-34.2%); Quick Assets: $27.6M.
    • FQ1 2016 Guidance: Sales: $2M.
    | Comment!
  • Wed, May 27, 5:40 PM
    • Neptune Technologies (NASDAQ:NEPT): FQ4 Net loss of $10.68M
    • Revenue of $4.02M (+9.5% Y/Y)
    • Press Release
    | 3 Comments
  • Wed, Jan. 14, 8:17 AM
    • Neptune Technologies & Bioressources (NEPT +2.2%) FQ3 results: Revenues: $4.7M (+4.4%); Adjusted EBITDA Loss: ($4.3M) (+27.1%); Net Income: $0.07M (+100.7%); Quick Assets: $34.6M.
    • No guidance given.
    | 1 Comment
  • Tue, Jan. 13, 5:15 PM
    • Neptune Technologies (NASDAQ:NEPT): FQ3 net income of $0.07M.
    • Revenue of $4.74M (+6.0% Y/Y) misses by $0.86M.
    • Press Release
    | Comment!
  • Tue, Jan. 6, 8:13 AM
    • Neptune Technologies & Bioressources (NASDAQ:NEPT) will report fiscal Q3 results on January 13 after the close. The conference call will begin the next day, January 14, at 9:00 am ET.
    • Consensus view is a loss of ($0.05) on revenues of $5.6M.
    | Comment!
  • Nov. 24, 2014, 7:38 AM
    • Neptune Technologies & Bioressources (NASDAQ:NEPT) appoints Jim Hamilton President and CEO effective February 2, 2015. He joins the firm from DSM Nutritional Products USA where he was VP Nutrition and Health, North America.
    | 1 Comment
  • Oct. 14, 2014, 12:44 PM
    | Comment!
  • Oct. 14, 2014, 8:54 AM
    • Neptune Technologies & Bioressources (NASDAQ:NEPT) fiscal Q2 results:Total Revenues: $2.6M (-50.9%); Neutraceutical Revenues: $2.6M (-48.5%); Adjusted EBITDA Loss: ($12.9M) (-112.6%); Net Loss: ($14.8M) (-193.9%).
    | Comment!
  • Oct. 14, 2014, 8:43 AM
    • Neptune Technologies (NASDAQ:NEPT): FQ2 Net loss of $14.8M
    • Revenue of $2.62M (-51.0% Y/Y) misses by $0.75M.
    • Press Release
    | 2 Comments
  • Oct. 8, 2014, 8:40 AM
    • Neptune Technologies & Bioressources (NASDAQ:NEPT) will report fiscal Q2 (quarter ended August 31) results on October 15 before the open. The conference call will begin at 9:00 am ET.
    • Consensus view is a loss of ($0.06) per share on revenues of $3.4M.
    | Comment!
  • Sep. 30, 2014, 7:46 AM
    • A 365-patient Phase 2 clinical trial evaluating the safety and efficacy of Acasti Pharmaceuticals' (NASDAQ:ACST) CaPre (highy purified omega-3 concentrate from krill oil) for the treatment of patients with hypertriglyceridemia met all primary and secondary endpoints.
    • The trial was a randomized, placebo-controlled, double-blind, dose-ranging study designed to assess CaPre's safety and efficacy in reducing triglyceride levels in patients with mild-to-severe hypertriglyceridemia taking daily doses of 1 gram or 2 grams of CaPre or placebo over a 12-week period. Approximately 90% of the patients had baseline triglycerides between 200 and 499 mg/dL. The remainder had triglycerides between 500 and 877 mg/dL.
    • The study met its primary endpoint of a statistically significant mean placebo-adjusted decrease in triglycerides from baseline to week 12. The CaPre 1 gram cohort showed a reduction of 36.4% and the CaPre 2 gram showed a reduction of 38.6%.
    • There was a statistically significant decrease of 5.3% from baseline in non-HDL-C compared to placebo. There was a slight increase in HDL-C for both the 1 gram and 2 gram doses.
    • Acasti expects complete results from the trial by the end of 2014. It plans to move forward with a Phase 3 trial and a regulatory submission for CaPre as a treatment for severe hypertriglyceridemia.
    • Related tickers: (NASDAQ:NEPT) (NASDAQ:AMRN)
    | Comment!
  • Sep. 23, 2014, 9:13 AM
    • Neptune Technologies & Bioressources (NASDAQ:NEPT) reports that its Sherbrooke plant is now operating at an annual production rate of 100 metric tons and customer shipments of manufactured krill oil products have commenced.
    • The company expects to increase Sherbrooke's annual production rate to 150 metric tons by October/November.
    | Comment!
Visit Seeking Alpha's
NEPT vs. ETF Alternatives
Company Description
Neptune Technologies & Bioressources Inc is a biotechnology company. The Company is engaged in the development, manufacture and commercialization of marinederived omega3 polyunsaturated fatty acids.
Sector: Healthcare
Industry: Biotechnology
Country: United States